Lead Product(s) : AUR200
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
Details : AUR200, a highly potent and specific immune modulator, is an IgG4 Fc-fusion protein, inhibits BAFF and APRIL, which is being investigated for autoimmune diseases.
Product Name : AUR200
Product Type : Protein
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : AUR200
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANG-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANGANY’s First Clinical Trial Concludes on Time and with Positive Results
Details : ANG-101 is a therapeutic vaccine that provides a disruptive disease-modifying approach for the treatment of cat allergy. It is being evaluated in phase 1 clinical trials for the same.
Product Name : ANG-101
Product Type : Vaccine
Upfront Cash : Inapplicable
January 29, 2024
Lead Product(s) : ANG-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANG-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ANG-101 is a therapeutic vaccine that provides a disruptive disease-modifying approach for the treatment of cat allergy. It is being evaluated in phase 1 clinical trials for the same.
Product Name : ANG-101
Product Type : Vaccine
Upfront Cash : Inapplicable
November 22, 2023
Lead Product(s) : ANG-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palmitoylethanolamide
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FSD-201 (palmitoylethanolamide) stabilizes mast cells and down-regulates pro-inflammatory cytokines to effectuate an anti-inflammatory response; it is also known to target the CB2 receptors of endocannabinoid system of human body.
Product Name : FSD-201
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2022
Lead Product(s) : Palmitoylethanolamide
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palmitoylethanolamide
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study
Details : Approval to initiate a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of ultra-micronized-PEA in normal healthy volunteers.
Product Name : FSD201
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 03, 2020
Lead Product(s) : Palmitoylethanolamide
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MetaBlok
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The three-day dosing of the additional eight volunteers will provide Arch supplemental dosing data, for review by the U.S. FDA, for its future Phase II trials.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 03, 2020
Lead Product(s) : MetaBlok
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LSALT Peptide
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arch Biopartners Safely Completes Expanded Dosing of METABLOK
Details : Final group received the highest daily dose of Metablok tested to date for three consecutive days and met the primary endpoints of safety and tolerability.
Product Name : MetaBlok
Product Type : Peptide
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : LSALT Peptide
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable